Management of Hypertension and Hyperglycemia in Patients with Diabetes

Monitoring and Adjustments

The American Diabetes Association recommends checking serum creatinine and potassium levels at least annually (or more frequently if eGFR <60 mL/min/1.73 m²) when patients are on metformin plus ACE inhibitor/ARB therapy 1, 2
The American Diabetes Association suggests assessing HbA1c 4-12 weeks after adding any glucose-lowering medication 3, 2
Regular review and adjustment of antihypertensive therapy every 2-4 weeks is recommended until blood pressure targets are achieved 4, 9, 7
Annual monitoring minimum for creatinine, eGFR, potassium, and lipid panel in patients on this regimen is advised 1, 3, 2

The American Heart Association recommends adding a dihydropyridine calcium channel blocker (CCB) as the preferred second agent for blood pressure control, creating the combination of ACE inhibitor/ARB plus CCB 4, 5, 6
Alternatively, adding a thiazide-like diuretic (chlorthalidone or indapamide preferred over hydrochlorothiazide for cardiovascular outcomes) to the ACE inhibitor/ARB is suggested 1, 3, 2
For resistant hypertension, adding a mineralocorticoid receptor antagonist (spironolactone or eplerenone) is recommended, with close monitoring of potassium and creatinine 1, 3, 2

The European Society of Cardiology advises against combining an ACE inhibitor with an ARB (dual RAS blockade), as this increases risk of end-stage renal disease, stroke, and hyperkalemia without additional cardiovascular benefit 8, 6, 7
The American Heart Association recommends avoiding beta-blockers combined with thiazide diuretics unless specifically indicated (prior MI, active angina, heart failure with reduced ejection fraction), as this combination increases risk of new-onset diabetes 4, 5, 6